Mads O. Maeng
Aalborg, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Real-World Outcomes after Switch to Aflibercept 8 mg in Neovascular AMD: Twelve Months Follow-up on 654 Eyes.
Journal: Retina (Philadelphia, Pa.)
Published: May 26, 2026
Orthokeratology and retinal risk: a new dimension in myopia control.
Journal: Translational pediatrics
Published: February 04, 2026
Real-world insights on switching aflibercept dosage for enhanced outcomes in age-related macular degeneration (RISE-AMD): Safety data.
Journal: Acta ophthalmologica
Published: January 05, 2026
Real-World Insights on Switching Aflibercept Dosage for Enhanced Outcomes in Retinal Vein Occlusion (RISE-RVO): visual, anatomical and durability outcomes.
Journal: The British journal of ophthalmology
Published: December 08, 2025
Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion.
Journal: Journal of personalized medicine
Published: September 09, 2023
90-day mortality risk related to postoperative potassium levels in patients undergoing coronary bypass surgery.
Journal: Journal of molecular and cellular cardiology plus
Published: February 26, 2023
Laser-Induced Porcine Model of Experimental Retinal Vein Occlusion: An Optimized Reproducible Approach.
Journal: Medicina (Kaunas, Lithuania)
Published: December 19, 2022
Dexamethasone Intravitreal Implant Is Active at the Molecular Level Eight Weeks after Implantation in Experimental Central Retinal Vein Occlusion.
Journal: Molecules (Basel, Switzerland)
Published: July 04, 2022
Showing 1-9 of 9
Last Updated: 09/26/2026